Search clinical trials for: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]

Total 107 results

Hoffmann-La Roche

Completed

A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.

Anemia

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

Renal Anemia, Chronic

Italy, Spain, Hong Kong, Taiwan, Hungary, Korea, Republic of, Australia, Canada, France, Germany, Greece, Belgium, Thailand, Poland, Russian Federation, Israel
Hoffmann-La Roche

Terminated

A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.

Anemia

Estonia, Latvia, Finland, Norway
Hoffmann-La Roche

Completed

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

Renal Anemia

Belgium, Romania, Australia, France, Spain, Hungary, Italy, Poland, Germany, Russian Federation, Thailand, Ukraine
Hoffmann-La Roche

Completed

A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy

Anemia

India
Hoffmann-La Roche

Completed

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Renal Insufficiency, Chronic | Anemia

United States, Spain, France, Hungary, Italy, Lithuania, Poland
Hoffmann-La Roche

Completed

A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Anemia

United States, Canada, United Kingdom, Mexico, Poland
Hoffmann-La Roche

Completed

A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia

Anemia

Egypt
Hoffmann-La Roche

Completed

An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)

Kidney Disease, Chronic

Slovenia
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis

Anemia

South Africa
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia

Anemia

Belgium
Hoffmann-La Roche

Completed

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Anemia

Italy, Spain, United States, Germany
Hoffmann-La Roche

Completed

A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Anemia

United States
Hoffmann-La Roche

Completed

A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.

Anemia

India
Hoffmann-La Roche

Terminated

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Anemia

United States
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Anemia

Belgium, Spain, United States, Sweden, Denmark, Taiwan, France, Italy, United Kingdom, New Zealand, South Africa, Hungary, Thailand, Mexico, Poland, Czech Republic, Puerto Rico, Finland, Brazil, Germany, Panama
Hoffmann-La Roche

Completed

Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis

Renal Impairment | Renal Anemia of Chronic Kidney Disease

Germany
Hoffmann-La Roche

Completed

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis (IMPACT)

Chronic Kidney Diseases

Israel
Hoffmann-La Roche

Completed

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Anemia

Belgium, Italy, Poland, Spain, Hong Kong, Canada, France, Greece, Czech Republic, Austria, Estonia, Hungary, Australia, Germany, Finland
Hoffmann-La Roche

Completed

A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Anemia

China, Hong Kong
Hoffmann-La Roche

Completed

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

Anemia

Belgium, France, Germany, Italy, Spain, United States, Australia, Sweden, Denmark, Taiwan, Greece, Netherlands, United Kingdom, South Africa, Switzerland, Austria, Thailand, Poland, Hungary, Russian Federation, Mexico, Czech Republic and more
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Anemia

Belgium, Italy, Spain, Canada, Denmark, France, Austria, Switzerland, Australia, Sweden, Finland, Germany
Hoffmann-La Roche

Completed

A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.

Anemia

China
Hoffmann-La Roche

Completed

A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients

Anemia

Italy, Spain, Australia, France, Canada, Germany, United Kingdom, Belgium, Austria, Switzerland, Netherlands, Denmark, Finland, Portugal
Hoffmann-La Roche

Completed

A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Anemia

Spain, United States, Czech Republic, Canada, Greece, Switzerland, Thailand, Poland, Russian Federation, Sweden, South Africa, Norway, Brazil
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.

Anemia

Russian Federation
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Anemia

Germany
Hoffmann-La Roche

Completed

A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)

Renal Anemia of Chronic Kidney Disease

France
Hoffmann-La Roche

Completed

A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Anemia

India
Hoffmann-La Roche

Terminated

A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia

Anemia

Indonesia
Hoffmann-La Roche

Completed

LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Anemia

Mexico, Colombia, Argentina, Venezuela, Brazil, Uruguay, Ecuador, Peru, Chile
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis (MERCUR)

Anemia

Germany
Hoffmann-La Roche

Terminated

A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.

Anemia

Costa Rica, Guatemala, Argentina, Brazil, Panama, Chile, Colombia, Ecuador, Peru, Venezuela
Hoffmann-La Roche

Completed

A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis (ALTITUD)

Anemia, Kidney Disease, Chronic

Mexico
Hoffmann-La Roche

Completed

A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis

Anemia

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients

Anemia

Philippines
Biocad

Completed

Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis

Anemia

Russian Federation, Belarus
Hoffmann-La Roche

Completed

STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients

Anemia

Czech Republic
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Anemia

Brazil
Hoffmann-La Roche

Completed

A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Anemia

France, Germany, Italy, United States, Taiwan, Canada, Puerto Rico, Spain, Thailand, Portugal, United Kingdom, Poland
Hoffmann-La Roche

Completed

A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia

Anemia

Taiwan
Hoffmann-La Roche

Completed

A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Anemia

Italy, Spain, France, Canada, Hungary, United States, Germany, Belgium, Poland, Australia, Israel, United Kingdom, Czech Republic
Hoffmann-La Roche

Withdrawn

A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Anemia

Denmark
Hoffmann-La Roche

Terminated

Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia

Anemia

Sweden
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia

Anemia

Spain
Hoffmann-La Roche

Terminated

A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant

Anemia

France, United Kingdom, Germany, Spain, Belgium, Italy
Hoffmann-La Roche

Completed

A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis

Anemia

Hungary
Hoffmann-La Roche

Completed

A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)

Kidney Disease, Chronic

Germany
Hoffmann-La Roche

Completed

A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia (CARISMA)

Anemia

Italy
Genexine, Inc.

Completed

Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)

Anemia | Chronic Kidney Disease

Korea, Republic of

3

Subscribe